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Objectives: To compare anti-obesity interventions in a single evidence synthesis framework. 

Methods: Electronic databases were searched for randomised controlled trials of orlistat, rimonabant or sibutramine reporting weight or body mass index (BMI) change from baseline at 3, 6 or 12 months. A mixed treatment comparison was used to combine direct and indirect trial evidence. 

Results: 94 studies involving 24,808 individuals were included, 83 trials included data on weight change and 41 on BMI change. All results are in comparison with placebo. The active drugs were all effective at reducing weight and BMI. At 3 months orlistat reduced weight by 2.65kg (95% Credibility interval (CrI) -4.00kg,-1.31kg). For sibutramine, 15mg gave a greater reduction than 10mg at 12 months, -6.35kg versus -5.42kg respectively. Rimonabant reduced weight by 11.23kg at 3 months and 4.55kg at 12 months. Lifestyle advice alone also reduced weight at 6 and 12 months, but was less effective than the pharmacological interventions. . 

Conclusions: Modest weight reductions were seen for all pharmacological interventions. Those interventions which have now been withdrawn from use (sibutramine and rimonabant) seem to be the most effective, implying there may be a place in clinical practice for similar drugs if side effects could be avoided.

Abbreviations: Body Mass Index (BMI); type 2 diabetes (T2DM); Sibutramine Cardiovascular Outcomes trial (SCOUT); mixed treatment comparison (MTC); Odds Ratio (OR); Credibility interval (CrI). 
INTRODUCTION
Obesity (defined as a Body Mass Index (BMI) ≥ 30 kg/m2) is a global public health problem. In 2005 the World Health Organization estimated that there were 1.6 billion overweight adults worldwide, of whom at least 400 million were obese. They projected that by 2015 approximately 2.3 billion adults would be overweight and over 700 million would be obese (). Excess adiposity is a risk factor for many chronic diseases, including type 2 diabetes and cardiovascular disease (). It is also linked to increased mortality, with those individuals with a BMI of above 40 kg/m2 having a relative risk of death of two times higher than those with a lower BMI (). However, previous studies have shown that even a modest reduction in weight has a positive impact on cardiovascular risk factors  ADDIN EN.CITE () and is associated with a reduced risk for both developing type 2 diabetes (T2DM) () and diabetes associated mortality (). 
Lifestyle interventions aimed at reducing calories, increasing physical activity and behavioural changes are currently recommended as the first-line approach for weight management (, ). Healthcare professionals should only consider introducing pharmacological therapies after lifestyle changes have been tried and evaluated. Bariatric surgery is less frequently recommended as a treatment option and in accordance with strict treatment criteria. Previously recommended pharmacological therapies include sibutramine, rimonabant and orlistat. Orlistat is a lipase inhibitor that reduces the absorption of dietary fat in the gastrointestinal tract (). Long-term use of orlistat has been shown to improve weight, waist circumference, BMI, blood pressure and cholesterol () but with a number of gastrointestinal side effects (). Orlistat is currently the only anti-obesity drug licensed worldwide for the long-term treatment of obesity.  Rimonabant and sibutramine are both centrally-acting appetite suppressants associated with modest weight losses. The marketing authorisation for rimonabant was suspended across the European Union following a review by the Committee for Medicinal Products for Human Use, which concluded that the benefits of rimonabant treatment did not outweigh the risks of psychiatric adverse reactions (). The marketing authorisation for sibutramine was suspended following a review by the European Medicines Agency. They concluded that the benefits of treatment with sibutramine did not outweigh the associated cardiovascular risks following the results of the Sibutramine Cardiovascular Outcomes trial (SCOUT) (, ). New drugs, some of which aim to use similar mechanisms to rimonabant and sibutramine without the off-target components, are currently in development (, ).






Literature search and inclusion criteria
We identified publications from searches of electronic databases up to January 2009 (Full details given in Supporting Material 1). The titles and abstracts of all studies identified by the electronic searches were screened for inclusion by one reviewer. The full texts of all studies found to be potentially relevant were sought and were assessed for inclusion by two independent reviewers. 

We included completed randomised controlled trials published in English comparing orlistat (120g 3 times daily), sibutramine (10mg, 15mg or 10mg increasing to 15mg once daily) or rimonabant (20mg once daily) to lifestyle advice (standard care), placebo or metformin. Studies were also included if they gave orlistat and sibutramine in combination. We excluded trials with a treatment period of less than 12 weeks. We also included head-to-head comparisons of the pharmacological agents.

Studies in adults who were overweight, obese or at high cardiovascular disease risk were included. High cardiovascular disease risk was defined as having one or more of the following conditions:  hypertension, T2DM, gestational diabetes, polycystic ovary syndrome, high cholesterol, metabolic syndrome, angina, coronary artery disease, and non alcoholic steatohepatitis. Studies were excluded if they included people with mental illness, for example binge eating. 

To be included, trials had to report one or more of the following outcomes measured at approximately 3,6 or 12 months: weight change from baseline; BMI change from baseline; number losing ≥5% body weight; number losing ≥10% body weight. 

Data extraction and quality assessment
Data were extracted using a standardised form which included the following fields: author, year of publication, country, population included (diabetic, obese with comorbidities, obese but otherwise healthy, or other), trial design, treatment length, follow-up length, study quality, interventions used, level of lifestyle/ physical activity advice, whether a wash in period was used, and if so how long and whether it used an active intervention, and baseline characteristics by trial arm.

Dietary and /or physical activity advice was categorised as either (i) standard – one visit with general dietary/ physical activity advice given or if patients were given a lifestyle leaflet or (ii) enhanced – more than one visit or patient given more than just advice. Due to the poor reporting of the lifestyle components of the interventions, we assumed that standard advice was given if dietary and /or physical activity advice was not mentioned, as this is standard care for overweight and obese patients. We also assumed that if diet (or physical activity) advice had been given this also included advice on physical activity (or diet) and therefore did not extract data on diet and physical activity separately. 

Outcome data could either be presented at the arm level (the change from baseline for each treatment) or as trial level differences (the difference between the two treatments at follow up). For the continuous outcomes (weight and BMI change) the mean change from baseline and standard error were extracted or calculated from extracted data if possible. For the binary outcomes (5% and 10% weight loss) the number achieving the target was extracted for each intervention. Where possible, data from intention-to-treat analyses were extracted. Data were only extracted from either the manuscript text or tables (no attempt was made to extract from figures). Where data were incomplete the corresponding author of the study was contacted. 

All studies were assessed for quality. The quality tool used was based on that developed by Jadad () with the addition of a score for allocation concealment, as suggested by Schulz et al ().

The review protocol is available from the authors on request.

Data synthesis and analysis
For each outcome at each time point, a pair-wise meta-analysis was carried out followed by an MTC meta-analysis. If outcome data were missing they were derived from related statistics where feasible. Where standard deviations for means were not reported these were estimated from ranges, p-values or 95% confidence intervals as appropriate (). Where data on baseline and follow-up weight/BMI were reported, the mean change was calculated and the standard deviation was imputed (). 

For the pair-wise analysis, studies were pooled using random effects models as studies were expected to be heterogeneous. Heterogeneity was assessed using the I2 statistic. Publication bias was assessed visually using contour-enhanced funnel plots for all comparisons which contained five or more studies. Pair-wise analysis was carried out in Stata (version 11.0). 

MTC methods were used to compare all interventions under investigation within a single model. Initially all outcome measures and time points were checked to make sure they formed closed networks (). Placebo was used as the reference category throughout. We used a logistic regression model for the binary outcomes and a linear regression model for the continuous outcomes (). 

All MTC analysis was conducted using a Markov chain Monte Carlo simulation method using the Bayesian software, WinBUGS (). Vague prior distributions were used for all parameters. For all outcomes a burn-in of 10,000 simulations was discarded and the results are presented based on a further 40,000 simulations. Convergence was checked visually using the history plots.  The goodness of fit was checked using the residual deviance. For each treatment the percentage of times that treatment gained the highest rank across all of the simulations was also calculated. Further details of the analysis are available on request from the corresponding author. 

We compared the results of the MTC to the pair-wise meta-analysis; the results were defined as inconsistent when the MTC estimate did not fall within the 95% confidence interval from the pair-wise meta analysis.

Where data were available we carried out a sensitivity analysis for the 12 month weight change outcome according to the following variables: intention-to-treat (excluding those where intention-to-treat had not been used or it was not clear which method had been used) and wash-in (excluding those studies which had used a wash-in phase). A wash-in is defined as a pre-trial practice whereby all eligible patients are given an intervention (either active or placebo) for a period to test compliance, only those who comply are then randomised into the trial. 
 







Searches identified 3,183 potentially relevant titles and/or abstracts and after removing duplicates 3,141 records were screened for eligibility. Subsequently 161 full texts were assessed. Of these 67 were excluded (see Supporting Material 2). Overall 94 studies were included in the meta-analysis (see Figure 1 and Supporting Material 3). Orlistat was assessed in 54 studies, 44 studies included sibutramine and five studies assessed rimonabant (Figure 1). The majority of trials (70, 74%) were carried out in North America and Europe from 1995 to 2008 (Table 1). Overall 24,808 individuals were included; the mean trial size was 264 (range 14 to 3,277), 59% included 100 or more participants. The mean length of intervention was 8.3 months (range 3 to 48). Forty five studies (47.9%) included enhanced lifestyle advice. A wash-in period was used in 44 (46.8%) of the studies. 

The results of the quality assessment are given in Table 1. All included studies were randomised but the randomisation procedure was described adequately in only 40% of studies. Twenty two (23.4%) studies had concealed allocation. The majority of studies were double blind (66, 70%). Participant flow was not described in 17 (18.3%) of the studies. The data extracted for each included study are given in Supporting Material 4.

Evidence synthesis 
The number of studies included in each network ranged from 1 to 32, median 19 (inter quartile range 8 to 27). Figure 2 shows the network diagram for weight change at 12 months (all networks shown in Supporting Material 5). Full results of all of the pair-wise and MTC analyses are presented in Supporting Material 6.

5% Weight loss
Across all time points the pharmacological treatments were more effective than placebo or lifestyle advice (Table 2). The odds of 5% weight loss were around 3-fold greater in the participants treated with orlistat compared to placebo at all three time points. Sibutramine 10mg and 15mg significantly increased the odds of achieving a 5% weight loss compared to placebo, with the greatest effect seen at 3 months (OR 5.87 (95% CrI 1.46 to 17.65) and 9.95 (95% CrI 3.10 to 32.71) for 10mg and 15mg respectively) and reducing over time.  At 3 months sibutramine 15mg had the largest probability (81.4%) of being the best intervention in terms of having a 5% body weight loss.  At 6 months the combination of orlistat and sibutramine was the most efficacious intervention compared to placebo (OR 16.99, 95% CrI 2.45 to 62.01). Data on rimonabant were only available at 12 months, with a significant increase in the odds of a 5% weight loss compared to placebo (OR 3.78, 95% CrI 2.39 to 5.79).
10% Weight loss
Only one three-arm trial reported data on 10% weight loss at 3 months and no statistically significant differences between placebo and sibutramine 10mg or sibutramine 15mg were seen. The active treatments (orlistat, sibutramine 10mg, sibutramine 15mg and a combination of orlistat and sibutramine) were all superior to placebo at 6 and 12 months. 

Weight change from baseline
There was moderate to high levels of heterogeneity seen for many of the pair-wise comparisons. At 3 months in comparison to placebo, the active drugs were all associated with greater weight loss, ranging from a mean change of -2.65kg (95% CrI -4.00 to -1.31) for orlistat to -11.23kg (95% CrI -17.17 to -5.15) for rimonabant. Similar results were seen at 6 and 12 months. Lifestyle advice was also more effective than placebo at 6 months (-1.95kg, 95% CrI -3.83 to -0.11) and 12 months (-2.89kg, 95% CrI -4.90 to -0.84). 

BMI change from baseline
In line with the results for weight change at 3 months, all active treatments were associated with significant reductions in BMI compared to placebo. No difference was seen between lifestyle advice only and placebo (0.50 kg/m2, 95% CrI -0.51 to 1.48). At 6 months none of the active treatments or lifestyle advice were significantly better than placebo. For example metformin was associated with an increase in BMI compared to placebo (0.18kg/m2, 95% CrI -4.05 to 4.37). At 12 months orlistat and sibutramine 15mg had significantly greater BMI reduction compared to placebo (Table 2). No difference was seen between sibutramine 10mg or lifestyle advice and placebo. Sibutramine 15mg had the largest probability (62.4%) of being the best intervention in terms of BMI reduction. 

Sensitivity analysis
Sensitivity analyses were carried out on the 12 month weight change outcome only. Including only trials which explicitly used an intention-to-treat analysis gave comparable results to the main analysis including all studies (Table 3). Excluding those studies which had used a wash-in period led to smaller average weight reductions compared to placebo. For example the main analysis showed that on average those taking sibutramine 15mg lost 6.35kg more than those taking placebo, this was reduced to 3.83kg when the wash-in studies were excluded (Table 3).

Covariate adjusted analysis




Table 4 shows the residual deviance for each of the models fitted. Overall, all models had an acceptable level of fit, with the residual deviance being roughly equal to the number of unconstrained data points in all cases. 

Inconsistency
The pair-wise and MTC results showed consistency for the 5% and 10% weight loss outcomes. Inconsistency between the pair-wise and MTC results was seen across all time points for both weight and BMI change. For example, for weight change at 3 months, there were 15 pair-wise comparisons, eight were consistent with the MTC results, seven were not, with the MTC results showing greater weight loss for the drug interventions than for the pair-wise results. 

Publication bias





This is the first MTC of anti-obesity treatments to have been carried out. It utilises cutting edge statistical methodology to compare treatments where no head-to-head trials have been carried out. Overall, the results show that the active drug interventions are all effective at reducing weight and BMI compared to placebo. Orlistat gave increased odds of achieving 5% body weight loss at 3, 6 and 12 months and 10% body weight loss at 6 and 12 months compared to placebo. Modest weight and BMI reductions were also seen at each time point. For sibutramine the higher dose (15mg) gave a greater reduction than the lower dose (10mg). Although data were limited, the combination of orlistat and sibutramine was also effective.  Additionally lifestyle advice (standard care) was shown to be better than placebo for weight loss at 6 and 12 months. The sensitivity analysis showed that using enhanced advice increased weight loss in the lifestyle group and, contrary to other studies, those with T2DM had a greater weight loss with both active intervention and lifestyle advice at 12 months (). 

Interestingly, our results show that those interventions which have now been withdrawn from use (sibutramine and rimonabant) seem to be the most effective in terms of weight loss compared to placebo, other studies have shown similar weight losses for orlistat as we have shown here for sibutramine and rimonabant (), implying there may be a place in clinical practice for similar drugs if the ‘off-target’ side effects could be avoided. In 2002 sibutramine was contraindicated in those with established coronary heart disease, previous stroke, heart failure or cardiac arrhythmias after post-marketing surveillance of adverse events. Since the initiation of this analysis the SCOUT trial has been published (). This trial confirmed that long-term use of sibutramine in those at high risk of cardiovascular disease was associated with an increased risk of nonfatal myocardial infarction and nonfatal stroke leading to the suspension of the drug. This trial was not included in the MTC analysis because it did not provide weight loss data at the time points of interest. However, the weight loss results of this trial are broadly in line with the results of the MTC and therefore, if the data had been available, the inclusion of this trial is unlikely to have changed the conclusions. Rimonabant was the first of a new class of agents that acts by selectively blocking the cannabinoid-1 receptors in the endocannabinoid system to reduce food intake. .Rimonabant had its licence withdrawn in 2009 due to psychiatric adverse reactions including depression, anxiety, irritability, aggression and suicide. Meta analyses have shown that rimonabant was associated with 1.4 times more serious adverse events compared to placebo, and that those taking rimonabant were  2.5 times more likely to discontinue the treatment because of depressive mood disorders than were those given placebo and 3 times more likely to discontinue because of anxiety (). A meta analysis of four large scale rimonabant trials showed that 6% of those receiving rimonabant experienced psychiatric side effects compared to 3% in the placebo group (). 

This is the first analysis of this kind to be carried out and there are a few limitations which should be considered. Firstly, inconsistency was seen between the results of the MTC and the pair-wise comparisons, with a higher level of inconsistency seen for weight and BMI change. There are many possible reasons for this.  The difference between the level of inconsistency between the binary and continuous outcomes might be explained by differences in the scale on which the data are collected; the binary outcome uses percentage weight change, whereas the continuous outcome uses the absolute change. In addition the binary outcomes were recorded in the same way across all trials; therefore the quality of the data is greater and less imputation and assumptions were required.  The level of publication bias could also add to the level of inconsistency seen and may have positively skewed the results found. Secondly, although this analysis has included data on 94 trials, generally the data quality of the trials included was low with poor reporting of standard errors and standard deviations. Studies with outlying standard deviations/errors were reassessed and where possible data were corrected. If the publication did not make clear which measure of variability had been used the more conservative estimate was used. This could affect the results of the MTC by giving larger variability to those studies which reported ambiguous results thus underestimating rather than overestimating any treatment effects. The way data were reported also varied by study. For the MTC we required change from baseline with standard error either for each treatment or between treatments. Many studies had reported absolute weight by treatment at baseline and follow up, in these cases change from baseline was calculated and the standard error was imputed. The imputed standard error uses a correlation coefficient which was calculated using trials where both the absolute and change in weight had been given (). No such data were available for BMI; therefore we assumed the correlation for BMI would be the same as for weight. Thirdly, we did not consider all possible comparators and therefore this is not a complete MTC analysis. The inclusion of studies was limited to those which included one of the active drugs against a limited number of comparators; therefore studies comparing lifestyle interventions alone were not included. Additionally, we also excluded all studies not reported in English (11 studies); although this could have biased the results, a number of studies have suggested that excluding non-English studies has minimal impact on the results found (). Therefore although 11 studies were excluded from this review on language grounds, this will probably have had either little or a conservative effect on the results found.  

This work has highlighted many areas of methodological research which could be explored including: assessing inconsistencies within a network to determine differences between the results of pair-wise and MTC analyses; the use of meta-regression methods to look for effect modifiers; exploring the effect of local publication bias; and the use of joint models to analyse the repeated measures of BMI and the time to event processes simultaneously.  From a clinical perspective, a long-term clinical trial for orlistat reporting hard clinical endpoints (cardiovascular events, onset of T2DM, incidence of cancer) would be particularly informative both from a clinical angle and to inform future economic evaluations.  Clinical data from sub-groups with high prevalence rates of obesity are also needed.  Finally, robust long term observational data in obese cohorts would be useful to inform the risk models which underpin the economic modelling.  
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FIGURE 1: Flow diagram
FIGURE 2: Network diagram for weight change at 12 months
TABLE 1: Characteristics of included trials 
TABLE 2: MTC Model results unadjusted for covariates
TABLE 3: Sensitivity and covariate adjusted analysis for 12 month weight change































Network diagram for weight change at 12 months







Characteristics of included trials 
Author (year)	Interventions	Country	Type RCT	Intervention Length (months)	Randomisation	AllocationConcealment	Double blinding	Participant flow	Diet	T2DM (%)	Wash in	LOCF
Apfelbaum (1999)	PlaceboSibutramine 10mg	France	Parallel	12	1	0	1	2	E	NRNR	Y	L
Avdikovsky (2007)	Lifestyle adviceOrlistat	Hungary	Parallel	6	1	0	0	0	S	NRNR	N	NR






























Florakis (2008)	Lifestyle adviceSibutramine 10mg	Greece	Parallel	6	2	1	0	2	S	NRNR	Y	C
Garcia (2006)	Lifestyle adviceOrlistat		Parallel	12	1	0	0	1	E	9.026.0	N	C
Gokcel (2002)	Sibutramine 10mgOrlistatMetformin	Turkey	Parallel	6	1	0	0	0	S	8.010.012.0	N	NR
Grudell (2008)	PlaceboSibutramine 10mgSibutramine 15mg	USA	Parallel	3	1	0	1	1	E	NRNRNR	N	NR












Kaya (2004)	Lifestyle adviceSibutramine 10mgOrlistatOrlistat & Sib	Turkey	Parallel	3	1	0	0	1	S	0000	N	NR
Kelley (2002)	PlaceboOrlistat	USA	Parallel	12	1	0	1	2	E	100100	N	NR
Kelley (2004)	PlaceboOrlistat	USA	Parallel	6	1	0	1	1	E	100100	N	C













Porter (2004)	Lifestyle adviceSibutramine 15mg	USA	Parallel	12	2	0	0	0	E	7.310.7	N	L
Poston (2003)	Lifestyle adviceOrlistat	USA	Parallel	12	1	0	0	2	E	9.612.7	N	L
Poston (2006)	Lifestyle adviceOrlistat	USA	Parallel	12	1	0	0	1	E	NRNR	N	L
Redmon (2003)	Lifestyle adviceSibutramine 15mg	USA	Parallel	12	2	1	0	1	E	100100	N	L
Rossner (2000)	Placebo Orlistat	Europe	Parallel	24	2	0	1	2	S	00	Y	L
Sarac (2006)	PlaceboSibutramine 10mg	Turkey	Parallel	3	1	0	1	0	S	NRNR	N	L
Sari (2004)endocrine	OrlistatSibutramine 15mgSib & Orlistat	Turkey	Parallel	6	1	0	0	1	E	000	N	C





Shechter (2006)	Lifestyle adviceSibutramine 10mg	Israel	Parallel	4	2	0	0	0	S	40.040.0	N	L
Shi (2005)	PlaceboOrlistat	China	Parallel	6	1	0	1	2	S	NRNR	N	L
Smith (2001)	PlaceboSibutramine 10mgSibutramine 15mg	UK	Parallel	12	2	1	2	2	S	000	Y	L
Swinburn (2005)	PlaceboOrlistat	Australia, New Zealand	Parallel	12	2	0	1	1	E	8.38.2	Y	L
Tambascia (2003)	PlaceboSibutramine 10mg	Brazil	Parallel	6	2	0	1	1	S	00	Y	C




Van Gaal (1998)	PlaceboOrlistat	Austria, Belgium, Brazil, Germany, Italy, Sweden, Switzerland, UK	Parallel	6	1	0	2	2	E	NRNR	Y	L
Van Gaal (2005)	PlaceboRimonbant	Europe & USA	Parallel	24	2	1	1	2	E	00	Y	NR
Vazquez Roque (2007)	PlaceboSibutramine 15mg	USA	Parallel	3	2	1	2	2	E	NRNR	N	L










MTC Model results unadjusted for covariates
		3 months	6 months	12 months
Outcome	Treatment	OR	95% CI	% best ranking	OR	95% CI	% best ranking	OR	95% CI	% best ranking
5% weight loss	Placebo	Reference		0	Reference		0	Reference		0
	Orlistat	3.86	0.06 to 15.11	2.5	2.95	1.62 to 4.97	0.1	2.89	2.22 to 3.72	2.0
	Sib 10mg	5.87	1.46 to 17.65	16.0	4.24	2.39 to 6.84	2.2	3.25	1.56 to 6.22	16.1
	Sib 15mg	9.95	3.10 to 32.71	81.4	6.90	3.49 to 12.99	21.5	4.06	2.51 to 6.29	47.3
	Rimonabant	-	-	-	-	-	-	3.78	2.39 to 5.79	34.5
	Orlistat and Sib	-	-	-	16.99	2.45 to 62.01	76.1	-	-	-
	Lifestyle advice	0.90	0.05 to 4.02)	0.01	0.39	0.10 to 1.04	0	1.01	0.42 to 2.06	0
10% weight loss	Placebo	Reference		4.2	Reference		0	Reference		0
	Orlistat	-	-	-	3.10	1.44 to 6.14	0	2.43	1.72 to 3.39	0.3
	Sib 10mg	16.41	0.34 to 93.23	55.1	6.57	3.28 to 12.97	1.3	3.38	1.39 to 7.13	10.7
	Sib 15mg	14.34	0.28 to 77.43	40.7	18.83	6.70 to 48.1	54.3	5.02	2.63 to 9.12	57.9
	Orlistat and Sib	-	-	-	22.96	2.82 to 88.08	43.3	-	-	-
	Rimonabant	-	-	-	-	-	-	4.25	2.35 to 7.31	31.2
	Lifestyle advice	-	-	-	2.76	0.21 to 12.1	1.0	-	-	-
		Mean difference	95% CI	% best ranking	Mean difference	95% CI	% best ranking	Mean difference	95% CI	% best ranking
Weight change	Placebo	Reference		0	Reference		0	Reference		0
	Orlistat	-2.65	-4.00 to -1.31	0	-3.08	-4.20 to -2.03	0	-4.12	-5.07 to 3.15	0.2
	Metformin	-4.63	-7.46 to -1.68	0	-3.15	-6.51 to 0.29	0.4	-	-	-
	Sib 10mg	-4.88	-6.40 to -3.43	0	-5.08	-6.55 to -3.62	1.3	-5.42	-7.36 to -3.42	16.6
	Sib 15mg	-5.37	-6.59 to -4.10	0	-6.11	-8.11 to -4.23	5.3	-6.35	-8.06 to -4.63	78.2
	Rimonabant	-11.23	-17.17 to -5.15	62.6	-	-	-	-4.55	-6.20 to -2.92	5.0
	Orlistat and Sib	-10.18	-13.82 to -6.59	37.7	-9.67	-14.32 to -5.04	93.1	-	-	-
	Lifestyle advice	-1.36	-3.23 to 0.48	0	-1.95	-3.83 to -0.11	0	-2.89	-4.90 to -0.84	0
BMI change	Placebo	Reference		0	Reference		0.1	Reference	-	0
	Orlistat	-1.56	-2.54 to -0.58	0	-0.59	-2.60 to 1.39	7.5	-1.43	-2.67 to -0.18	1.8
	Metformin	-3.50	-5.02 to -1.87	0.6	0.18	-4.05 to 4.37	13.2	-	-	-
	Sib 10mg	-2.43	-3.33 to -1.54	0.1	-0.95	-2.89 to 1.02	16.4	-2.27	-5.08 to 0.59	33.0
	Sib 15mg	-2.25	-2.97 to -1.54	0	-1.81	-4.25 to 0.61	60.6	-2.91	-5.45 to -0.62	62.4
	Rimonabant	-6.24	-9.07 to -3.33	95.5	-	-	-	-	-	-
	Orlistat and Sib	-3.16	-5.22 to -1.11	3.7	-	-	-	-	-	-





Sensitivity and covariate adjusted analysis for 12 month weight change
		Mean difference	95% CI	% best ranking 
Excluding wash in studies	Placebo	Reference		0
	Orlistat	-2.79	-3.56 to -2.04	5.0
	Sib 10mg	-	-	-
	Sib 15mg	-3.83	-5.06 to -2.68	95.0
	Rimonabant	-	-	-
	Lifestyle advice	0.82	-0.40 to 2.06	0
LOCF only	Placebo	Reference		0
	Orlistat	-4.23 	-5.52 to -2.92	2.1
	Sib 10mg	-5.44	-7.67 to -3.13	17.2
	Sib 15mg	-6.49	-8.89 to -4.09	73.5
	Rimonabant	-3.94	-6.04 to -1.75	3.5
	Lifestyle advice	-1.99	-7.73 to 3.67	3.8
T2DM only	Placebo	Reference		0
	Orlistat	-5.53 	-7.97 to -3.06	9.2
	Sib 10mg	-3.91	-13.41 to 7.55	13.7
	Sib 15mg	-7.17	-11.24 to -3.00	33.9
	Rimonabant	-4.71	-9.09 to 0.04	8.7
	Lifestyle advice	-7.19	-12.98 to -2.17	34.4
No T2DM only	Placebo	Reference		0
	Orlistat	-2.44	-4.23 to -0.60	0.5
	Sib 10mg	-2.61	-6.16 to 0.86	1.8
	Sib 15mg	-6.21	-9.77 to -2.74	86.6
	Rimonabant	-3.43	-6.63 to -0.36	10.5
	Lifestyle advice	-2.47	-5.66 to 0.77	0.6
Enhanced diet and/or physical activity only	Placebo	Reference		0
	Orlistat	-3.49	-5.22 to -1.74	0.2
	Sib 10mg	-5.39	-9.17 to -1.71	31.9
	Sib 15mg	-5.99	-8.92 to -3.15	46.6
	Rimonabant	-4.96	-8.15 to -1.75	21.0
	Lifestyle advice	-3.23	-5.97 to -0.47	0.2
Standard diet and/or physical activity only	Placebo	Reference		0
	Orlistat	-4.38	-6.37 to -2.37	9.6
	Sib 10mg	-1.26	-5.62 to 3.02	0.1
	Sib 15mg	-6.49	-10.91 to -2.17	60.1
	Rimonabant	-4.16	-8.69 to 0.41	13.7





Model fit assessed using the residual deviance










Weight change – T2DM covariate	12	51.348	51
Weight change – Diet covariate	12	63.156	63
Weight change – LOCF only	12	38.999	39






























I.e. Review articles; lab based studies; Editorials; RCTs not including interventions of interest; Observational studies






Sibutramine given in combination with another drug n=2
Ineligible drug dose n=6





Sub study of included trial n=10
Follow up data not at 3, 6 or 12 months n=7
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